Doctors in an unnamed medical centre have performed what is believed to be the first-ever injection of a patient's own mitochondria into her eyes. The procedure involved taking a small sample of muscle tissue from the patient's leg, isolating the mitochondria — the energy-producing organelles within cells — and injecting them into the eye in a targeted effort to replace or boost failing mitochondria in retinal cells.
The patient suffers from a mitochondrial disorder that had progressively damaged her vision. Mitochondrial diseases often affect tissues with high energy demands, such as the eyes, heart, and brain. Leber's hereditary optic neuropathy (LHON), for example, is a well-known mitochondrial condition that leads to sudden vision loss, typically in young adults.
While the exact condition treated in this case has not been disclosed, the rationale is straightforward: if the eye's own mitochondria are defective, transplanting healthy mitochondria from elsewhere in the body may restore cellular energy production and halt or reverse vision loss.
Previous preclinical studies in animals have shown that mitochondrial transfer can improve function in damaged tissues, but translating that to humans — and specifically to the delicate environment of the eye — presents significant challenges. The injection must be precise, the immune response must be managed, and the transplanted mitochondria must integrate with the host cells to function properly.
The surgeon who led the procedure, speaking on condition of anonymity, described the operation as 'technically successful,' though it is too early to assess whether the patient's vision has improved. The team plans to monitor her closely over the coming months and report results in a peer-reviewed journal.
If proven safe and effective, the technique could open a new avenue for treating not only mitochondrial eye diseases but also age-related macular degeneration and other retinal conditions where mitochondrial dysfunction plays a role. However, sceptics point out that the field of mitochondrial transplantation is still in its infancy, with unresolved questions about how long transplanted mitochondria survive, whether they can replicate inside host cells, and what the long-term risks might be.
Ethical oversight and regulatory approvals for such first-in-human procedures are typically stringent. It is unclear whether this surgery was performed under a clinical trial protocol or as a compassionate use exception. The involved institution has not yet announced plans for a formal trial.